Archon emerges from stealth with $20M and ‘antibody cages’ to power up drug development

Share via:


Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Archon emerges from stealth with $20M and ‘antibody cages’ to power up drug development


Archon Biosciences, a biotech startup putting AI to work designing novel biomolecules, has just emerged from stealth with an impressive $20 million in seed funding. The company aims to supercharge antibody treatments using specially designed protein “cages” that multiply their effects, opening up new opportunities in drug development.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

This Week in AI: A preview of Disrupt 2024’s...

Hiya, folks, welcome to TechCrunch’s regular AI newsletter....

Equity Live: Bret Taylor’s $4.5 billion startup and Waymo’s...

The Equity crew was live at TechCrunch Disrupt 2024!...

Betaworks focuses on AI applications in its latest Camp

For its most recent Camp, VC and accelerator...

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!